PubMedCrossRef 25 Aperis G, Fuchs BB, Anderson CA, Warner JE, Ca

PubMedCrossRef 25. Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB, Mylonakis E: Galleria mellonella as a model host to study infection MRT67307 by the Francisella tularensis live vaccine strain. Microbes Infect 2007, 9:729–734.PubMedCrossRef 26. Seed KD, Dennis JJ: Development of Galleria mellonella as an alternative infection model for the Burkholderia

cepacia complex. Infect Immun 2008, 76:1267–1275.PubMedCrossRef 27. Ikaheimo I, Syrjala H, Karhukorpi J, Schildt R, Koskela M: In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000, 46:287–290.PubMedCrossRef 28. Urich SK, Petersen JM: In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother 2008, 52:2276–2278.PubMedCrossRef 29. Mason WL, Eigelsbach HT, Little SF, Bates JH: Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir

Dis 1980, 121:39–45.PubMed 30. Lai XH, Golovliov I, Sjostedt A: Francisella tularensis induces cytopathogenicity and apoptosis in murine macrophages via a mechanism that requires intracellular bacterial multiplication. Infect Immun 2001, 69:4691–4694.PubMedCrossRef 31. Saha S, Savage PB, Bal M: Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens. J Appl Microbiol 2008, 105:822–828.PubMedCrossRef 32. Marinov KT, Georgieva ED,

MM-102 nmr {Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|buy Anti-cancer Compound Library|Anti-cancer Compound Library ic50|Anti-cancer Compound Library price|Anti-cancer Compound Library cost|Anti-cancer Compound Library solubility dmso|Anti-cancer Compound Library purchase|Anti-cancer Compound Library manufacturer|Anti-cancer Compound Library research buy|Anti-cancer Compound Library order|Anti-cancer Compound Library mouse|Anti-cancer Compound Library chemical structure|Anti-cancer Compound Library mw|Anti-cancer Compound Library molecular weight|Anti-cancer Compound Library datasheet|Anti-cancer Compound Library supplier|Anti-cancer Compound Library in vitro|Anti-cancer Compound Library cell line|Anti-cancer Compound Library concentration|Anti-cancer Compound Library nmr|Anti-cancer Compound Library in vivo|Anti-cancer Compound Library clinical trial|Anti-cancer Compound Library cell assay|Anti-cancer Compound Library screening|Anti-cancer Compound Library high throughput|buy Anticancer Compound Library|Anticancer Compound Library ic50|Anticancer Compound Library price|Anticancer Compound Library cost|Anticancer Compound Library solubility dmso|Anticancer Compound Library purchase|Anticancer Compound Library manufacturer|Anticancer Compound Library research buy|Anticancer Compound Library order|Anticancer Compound Library chemical structure|Anticancer Compound Library datasheet|Anticancer Compound Library supplier|Anticancer Compound Library in vitro|Anticancer Compound Library cell line|Anticancer Compound Library concentration|Anticancer Compound Library clinical trial|Anticancer Compound Library cell assay|Anticancer Compound Library screening|Anticancer Compound Library high throughput|Anti-cancer Compound high throughput screening| Ivanov IN, Kantardjiev TV: Characterization and genotyping of strains of Francisella tularensis isolated in Bulgaria. J Med Microbiol 2009, 58:82–85.PubMedCrossRef 33. Pechere JC: Macrolide resistance mechanisms in Gram-positive cocci. Int J Antimicrob Agents 2001,18(Suppl 1):S25–28.PubMedCrossRef Racecadotril 34. Larsson P, Oyston PC, Chain P, Chu MC, Duffield M, Fuxelius HH, Garcia E, Halltorp G, Johansson D, Isherwood KE, et al.: The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet 2005, 37:153–159.PubMedCrossRef 35. Champion MD, Zeng Q, Nix EB, Nano FE, Keim P, Kodira CD, Borowsky M, Young S, Koehrsen M, Engels R, et al.: Comparative genomic characterization of Francisella tularensis strains belonging to low and high virulence subspecies. PLoS Pathog 2009, 5:e1000459.PubMedCrossRef 36. Piddock LJ: Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006, 19:382–402.PubMedCrossRef 37. Misra R, Reeves PR: Role of micF in the tolC-mediated regulation of OmpF, a major outer membrane protein of Escherichia coli K-12. J Bacteriol 1987, 169:4722–4730.PubMed 38. Biswas S, Raoult D, Rolain JM: A bioinformatic approach to understanding antibiotic resistance in intracellular bacteria through whole genome analysis. Int J Antimicrob Agents 2008, 32:207–220.PubMedCrossRef 39.

Comments are closed.